A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
Status:
Completed
Trial end date:
2020-11-20
Target enrollment:
Participant gender:
Summary
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by
FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug
Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection,
in the "off-label" mode, to make a decision on the possibility of expanding the indications
for use.